Beam Wealth Advisors Inc. Grows Position in Pfizer Inc. (NYSE:PFE)

Beam Wealth Advisors Inc. boosted its holdings in Pfizer Inc. (NYSE:PFE) by 1.5% in the 4th quarter, HoldingsChannel reports. The fund owned 27,444 shares of the biopharmaceutical company’s stock after acquiring an additional 401 shares during the quarter. Beam Wealth Advisors Inc.’s holdings in Pfizer were worth $728,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the business. Retirement Wealth Solutions LLC acquired a new stake in Pfizer in the fourth quarter valued at $26,000. Gladius Capital Management LP grew its holdings in Pfizer by 102.8% in the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 38,015 shares during the last quarter. Kohmann Bosshard Financial Services LLC acquired a new stake in Pfizer in the fourth quarter valued at $28,000. Noble Wealth Management PBC acquired a new stake in Pfizer in the fourth quarter valued at $31,000. Finally, Teachers Insurance & Annuity Association of America acquired a new stake in Pfizer in the third quarter valued at $35,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Insider Transactions at Pfizer

In related news, Director Ronald E. Blaylock bought 19,457 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The shares were acquired at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the acquisition, the director now owns 27,707 shares in the company, valued at $710,684.55. This represents a 235.84 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 0.06% of the company’s stock.

Pfizer Stock Up 1.0 %

Shares of NYSE:PFE opened at $26.21 on Friday. The stock’s 50-day moving average price is $26.30 and its two-hundred day moving average price is $27.26. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54. The firm has a market cap of $148.51 billion, a price-to-earnings ratio of 18.59, a PEG ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. The firm had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm’s quarterly revenue was up 24.7% on a year-over-year basis. During the same period last year, the company earned $0.10 EPS. On average, research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.56%. This is an increase from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. Pfizer’s dividend payout ratio (DPR) is 121.99%.

Analyst Upgrades and Downgrades

Several research firms have weighed in on PFE. Wolfe Research began coverage on Pfizer in a report on Friday, November 15th. They issued an “underperform” rating and a $25.00 target price on the stock. Citigroup lowered their target price on Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. UBS Group decreased their price objective on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 8th. Truist Financial decreased their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. Finally, StockNews.com lowered Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. One analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.